Arvinas (ARVN) EBITDA Margin (QoQ) (2017 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EBITDA Margin (QoQ) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Arvinas | 605.88 Mn | 37.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47,469.00 |
| Mar 31, 2026 | 37,629.00 |
| Dec 31, 2025 | -68,073.00 |
| Sep 30, 2025 | 21,466.00 |
| Jun 30, 2025 | -35,701.00 |
| Mar 31, 2025 | 13,613.00 |
| Dec 31, 2024 | -3,942.00 |
| Sep 30, 2024 | 451.00 |
| Jun 30, 2024 | 26,585.00 |
| Mar 31, 2024 | -71,278.00 |
| Dec 31, 2023 | 59,711.00 |
| Sep 30, 2023 | -7,670.00 |
| Jun 30, 2023 | 13,297.00 |
| Mar 31, 2023 | -6,985.00 |
| Dec 31, 2022 | -633.00 |
| Sep 30, 2022 | 100.00 |
| Jun 30, 2022 | 2,306.00 |
| Mar 31, 2022 | -7,466.00 |
| Dec 31, 2021 | 36,553.00 |
| Sep 30, 2021 | 43,503.00 |